Post-traumatic stress disorder (PTSD)

Post-traumatic stress disorder (PTSD) is a mental health disorder
developed after having experienced or witnessed traumatic events (terrorist attacks, muggings, violent assaults, rape, traffic accident, admission to the ICU, etc.) that occurs with the appearance of symptoms that seriously alter the daily life of the patient. It is natural to feel fear before a traumatic situation or after it. This fear causes many changes in the body in fractions of a second aimed at responding to the danger in question in order to avoid it in the future. This “fight or flight” response is a typical reaction that serves to protect the person from any danger. Almost everyone will have a series of reactions associated with this response after a traumatic experience. Although most people recover on their own from the natural stress of a traumatic exposure, 3.5% of the general population and up to 25-32% of exposed groups (soldiers, police, emergency health workers…) are unable to control the stress response and end up developing PTSD, where their lives are severely conditioned. In some cases, PTSD symptoms can start later. They can also come and go over time.
Prevalence and causes
GENERAL PREVALENCE
19-75% 75%
Physical/Sexual Aggression
52%
Accidents and Injuries
36%
Natural Disasters
30-40% 40%
Heart Conditions
12%
ICU Patients - post COVID19
25%

Exposed Personnel

UCI Covid 19 patients
8%
Police, Health Care Workers, Firefighters…
15%
Soldiers
(6-32%) 25%

PRECLINIAL PHASE

Results of memory consolidation in mouse

UNTIL NOW

NO EFFECTIVE TREATMENT

PROCESS: Memory Consolidation, selective therapeutic window for PTSD
GREAT NEED of a causal approach, specific, efficient, short and economic to find a CURE!
Our Target: CPEB3
A protein that acts like an “switch” of long term memory.
CONCEPTUAL ADVANTAGES
Aimed at the cause of the illness (not just the symptoms). Impedes the consolidation of traumatic memory. Specific to long term memory (does not affect short term memory) Does not erase prior memories: only impedes the consolidation of new memories.

PROPOSED SOLUTION

QBP1 as an inhibitor of CPEB3 activation

The peptide QBP1 as prevention and therapy for PTSD

(OUR DRUG CANDIDATE)

European Patent

Nº: 3280430

All search reports conducted indicate that the patent is “clean”: no competition. Feedom to Operate
The technology on which our startup is based is the QBP1 peptide: it is an amyloid inhibitor that prevents the amyloidogenesis of the CPEB3 protein in mammals, thereby blocking its activation and the consequent specific consolidation of new memories (without affecting previous memories or short-term memory). The QBP1 peptide is the basis of the drug that is intended to be developed to prevent and treat PTSD. This technology has been protected by a European patent in national phases in Europe (P1672503):

RELATED ARTICLES
(PUBLISHED and PENDING)

• López-García, P., et al and Carrión-Vázquez M. (enviado a publicar) (2020). Blockade of memory consolidation in mouse by an anti-amyloidogenic peptide. Reports the blocking of CPEB by QBP1 both in vitro and in vivo (in mouse). bioRxiv doi: 10.1101/2020.01.21.913053
• Hervás, R.,...and Carrión-Vázquez, M. (2016) Molecular basis of Orb2 amyloidogenesis and blockade of memory consolidation. PLoS Biology. doi: 10.1371/journal.pbio.1002361. Reports the blocking of consolidation of memory by QBP1 in Drosophila.
• Ramírez de Mingo D, Pantoja-Uceda D, Carrión-Vázquez M, Laurents DV (2020). Preferred conformations in the intrinsically disordered region of human CPEB3 explain its role in memory consolidation. bioRxiv doi:10.1101/2020.05.12.091587.
• Hervás, R., Fernández-Ramírez, M.C., Galera-Prat, A., Suzuki, M., Nagai, Y., Bruix, M., Menéndez, M., Laurents, D.V., and Carrión-Vázquez, M. (2020). Divergent CPEB prion-like domains reveal different assembly mechanisms for a generic amyloid-like fold. BioRxiv. DOI:10.1101/2020.05.19.103804.
• Ramos-Martín, F., Hervás, R., Carrión Vázquez, M & Laurents, D.V. (2014). Arch. Biochem. Biophys. 558:104-110. Reports the structure of QBP1 (by NMR).

Discuss With Us For Your Research Needs

Dr. Mariano Carrión Vázquez
Dr. Ismael San Mauro Martín

Main office and lab - Instituto Cajal (CSIC)

Avenida del Dr. Arce, 37, 28002 Madrid

Follow My Social Media :

 

Dont like Filling up forms ? Mail us then

Data controller: Disrupep s.l., responsible for this website Purpose of the data: Manage the request you make in this contact form. Data storage: Database hosted on siteground spain sl Rights: At any time you can limit, recover and delete your information. For more information: Privacy Policy